Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06189703 · ClinicalTrials.gov registry record · NA

tRNS Treatment for ADHD Symptoms

A NA study of ADHD, sponsored by Innosphere.

Active
Registry status
NA
Development phase
146
Enrollment target
5
Study locations

NCT06189703 is a NA study of ADHD that is active but no longer recruiting, run by Innosphere. The registered enrollment target is 146 participants, below the 188-participant average among 75 other ADHD trials with a reported enrollment target (22% lower). The trial reports 5 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06189703, a NA study of ADHD, is active but no longer recruiting, sponsored by Innosphere.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
146 participants
Enrollment target
5
Study locations

Study Summary

A randomized, sham-controlled, double-blind clinical trial to examine the safety and effectiveness of tRNS on unmedicated pediatric patients (7-12 years) with ADHD. Subjects will undergo either tRNS or sham treatment for 10 days during a two-week period in a home-simulated environment. Each treatment session is 20 minutes, during which their attention will be maintained using a software game.

Conditions Studied

Interventions

  • DEVICE tRNS

Study Locations (5)

Texas

  • Baylor College of Medicine Department of Psychiatry & Behavioral Sciences - Houston
  • UTHealth Houston - Houston

Massachusetts

  • Boston Children's Hospital - Boston

Minnesota

  • Mayo Clinic Hospital, Methodist Campus - Rochester

Other

  • Hadassah Medical Center - Jerusalem

Trial Details

FieldValue
Enrollment Target 146 participants
Start Date 2024-07-15
Est. Completion 2026-05-30
Phase NA

Sponsor

Innosphere

1 total trials

What the Registry Record Tells You About NCT06189703

The ClinicalTrials.gov registry entry for NCT06189703 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 146 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 188-participant average among 75 other ADHD trials with a reported enrollment target (22% lower). The listed sponsor is Innosphere, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with ADHD appearing as the primary indexed condition, and to 1 intervention - of which tRNS is the first listed.

NCT06189703 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Texas, Massachusetts, Minnesota.

Frequently Asked Questions

What is clinical trial NCT06189703 about?

NCT06189703 is a clinical study titled "tRNS Treatment for ADHD Symptoms". A randomized, sham-controlled, double-blind clinical trial to examine the safety and effectiveness of tRNS on unmedicated pediatric patients (7-12 years) with ADHD. Subjects will undergo either tRNS or sham treatment for 10 days during a two-week period in a home-simulated environment. Each treatmen...

What is the current status of trial NCT06189703?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 146 participants. The study started on 2024-07-15. Estimated completion is 2026-05-30.

What conditions does trial NCT06189703 study?

This clinical trial studies the following conditions: ADHD.

What interventions are being tested in trial NCT06189703?

The interventions under investigation include: tRNS (DEVICE).

Who is sponsoring clinical trial NCT06189703?

This trial is sponsored by Innosphere, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06189703 being conducted?

This trial has 5 study locations across Massachusetts, Minnesota, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for ADHD

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.